Clinical significance in the change of decline in ALSFRS-R
about
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Subjects no more: what happens when trial participants realize they hold the power?Amyotrophic lateral sclerosis disease progression model.Influence of Resistance Training on Neuromuscular Function and Physical Capacity in ALS Patients.Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm.Non-self-sufficiency as a primary outcome measure in ALS trials.Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort.A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials.Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial.Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.Multiparametric Analysis of Sniff Nasal Inspiratory Pressure Test in Middle Stage Amyotrophic Lateral Sclerosis.Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction.The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosisDexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics
P2860
Q28649394-84DBB445-147A-4F9D-8FDB-C85E3330DDD6Q28659882-2E8F1356-5FDC-4E6F-9246-B5866ECCA8EEQ30486384-DB5E66DD-20D3-414B-B7AD-CF0595F39B9EQ33741341-E03801C7-FF85-469A-A991-94F877AEB481Q33880795-6B8585B6-CF6E-4454-A69F-1EFE817B4414Q39215223-0D870063-B624-41E0-88C1-22E6A10353DBQ41553914-591E2167-CA14-4806-AA91-A407C945D3ACQ47648367-DE9DB936-57B0-4286-8ED7-42EA4AB4C9D2Q47680014-5B21874E-E628-45D0-A58F-AF88A0F543DDQ47772089-CD38B995-346D-41CE-88E9-EDB712DA5C04Q48671390-4DEDE602-6BEB-4667-8E32-F88DB4EF0098Q49222007-C629BFD0-B478-4775-8553-9D41EA9FCA0CQ55284817-3A555F87-8688-4757-84FA-50A1856C6E18Q55368834-A8D0713F-D74E-4286-8431-08932AAA461AQ56773744-AA3A58FF-9933-4F9C-83A6-E6ABAAAEE63AQ58125542-9472BC12-F809-4DB3-A123-CEE9A1CF447A
P2860
Clinical significance in the change of decline in ALSFRS-R
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical significance in the change of decline in ALSFRS-R
@ast
Clinical significance in the change of decline in ALSFRS-R
@en
Clinical significance in the change of decline in ALSFRS-R
@en-gb
Clinical significance in the change of decline in ALSFRS-R
@nl
type
label
Clinical significance in the change of decline in ALSFRS-R
@ast
Clinical significance in the change of decline in ALSFRS-R
@en
Clinical significance in the change of decline in ALSFRS-R
@en-gb
Clinical significance in the change of decline in ALSFRS-R
@nl
prefLabel
Clinical significance in the change of decline in ALSFRS-R
@ast
Clinical significance in the change of decline in ALSFRS-R
@en
Clinical significance in the change of decline in ALSFRS-R
@en-gb
Clinical significance in the change of decline in ALSFRS-R
@nl
P2093
P2860
P1476
Clinical significance in the change of decline in ALSFRS-R
@en
P2093
Carmen Castrillo-Viguera
Elizabeth Simpson
Jeremy Shefner
P2860
P304
P356
10.3109/17482960903093710
P407
P577
2010-01-01T00:00:00Z